| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9273503 | Seminarios de la Fundación Española de Reumatología | 2005 | 9 Pages |
Abstract
Preliminary results suggest that tumoral necrosis factor alpha blocking agents, infliximab and etanercept, may be effective in SAPHO syndrome.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Ángel GarcÃa-Aparicio,